Mitiglinide

Mitiglinide

Systematic (IUPAC) name
(2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	oral
Identifiers
CAS Number	145375-43-5 N
ATC code	A10BX08 (WHO)
PubChem	CID: 121891
DrugBank	DB01252 Y
ChemSpider	108739 Y
UNII	D86I0XLB13 Y
KEGG	D01854 Y
ChEMBL	CHEMBL471498 Y
Chemical data
Formula	C19H25NO3
Molecular mass	315.41 g/mol
SMILES O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 Y Key:WPGGHFDDFPHPOB-BBWFWOEESA-N Y
NY (what is this?)  (verify)

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

External links

• Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.